Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Psychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00213-012-2796-8PMID 22782459
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of immune dysfunction in the pathophysiology of autism.

  2012influential reference
• Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial

  2012cited by this paper
• A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders

  2012cited by this paper
• Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

  2012cited by this paper
• IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation

  2011influential reference
• The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway

  2011cited by this paper
• Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome.

  2011influential reference
• A Study of Nuclear Transcription Factor-Kappa B in Childhood Autism

  2011cited by this paper
• Macrophage migration inhibitory factor activates cyclooxygenase 2–prostaglandin E2 in cultured spinal microglia

  2011cited by this paper
• Expression Profiling of Autism Candidate Genes during Human Brain Development Implicates Central Immune Signaling Pathways

  2011influential reference
• Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology

  2011cited by this paper
• Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder.

  2010cited by this paper
• Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.

  2010cited by this paper
• The immune system's role in the biology of autism

  2010cited by this paper
• Differential monocyte responses to TLR ligands in children with autism spectrum disorders.

  2010cited by this paper
• Immune dysfunction in autism: A pathway to treatment

  2010cited by this paper
• Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.

  2010cited by this paper
• Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders.

  2009influential reference
• Multiple pathways in prevention of immune-mediated brain disorders: Implications for the prevention of autism.

  2009cited by this paper
• Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

  2009cited by this paper
• Immune involvement in schizophrenia and autism: etiology, pathology and animal models.

  2009cited by this paper
• S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity

  2008cited by this paper
• Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL-2 and IL-15.

  2008cited by this paper
• Macrophage Migration Inhibitory Factor and Autism Spectrum Disorders

  2008cited by this paper
• Immune transcriptome alterations in the temporal cortex of subjects with autism.

  2008cited by this paper
• A Double-blind Placebo Controlled Trial of Piracetam Added to Risperidone in Patients with Autistic Disorder

  2008cited by this paper
• Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

  2008cited by this paper
• Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects

  2008cited by this paper
• Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms

  2008cited by this paper
• Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.

  2007cited by this paper
• Brain‐Specific Autoantibodies in the Plasma of Subjects with Autistic Spectrum Disorder

  2007cited by this paper
• Effect of pioglitazone treatment on behavioral symptoms in autistic children

  2007cited by this paper
• The immune response in autism: a new frontier for autism research

  2006cited by this paper
• The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

  2006cited by this paper
• Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity

  2006cited by this paper
• Neuroglial activation and neuroinflammation in the brain of patients with autism

  2005cited by this paper
• Immunological findings in autism.

  2005influential reference
• Cerebrospinal fluid and serum markers of inflammation in autism.

  2005cited by this paper
• A Review of Autism and the Immune Response

  2004cited by this paper
• Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2.

  2002cited by this paper
• Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

  2002cited by this paper
• The selective cyclooxygenase‐2 inhibitor rofecoxib reduces kainate‐induced cell death in the rat hippocampus

  2001cited by this paper
• Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression.

  2001influential reference
• The Immune System and Schizophrenia: An Integrative View

  2000cited by this paper
• Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages.

  1995cited by this paper
• Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

  1994cited by this paper
• The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

  1985influential reference
• PSYCHOPHARMACOLOGY

  1957cited by this paper
• Journal of Neuroinflammation Interleukin-1β and Anaphylatoxins Exert a Synergistic Effect on Ngf Expression by Astrocytes

  year unknowncited by this paper

• Challenging behaviors in adolescents with intellectual and developmental disabilities: current pharmacological perspectives.

  2026cites this paper
• Cerebellar Abnormalities: A Component of Autism Pathophysiology

  2026cites this paper
• The Role of Oxidative Stress in Autism Spectrum Disorder Pathophysiology, Diagnosis and Treatment

  2025cites this paper
• Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options

  2025cites this paper
• Genetic and Pathogenic Overlaps Between Autism Spectrum Disorder and Alzheimer’s Disease: Evolutionary Features and Opportunities for Drug Repurposing

  2025cites this paper
• Deciphering the molecular connections between polycystic ovarian syndrome and autism spectrum disorder using bioinformatic analysis.

  2025cites this paper
• Pharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy

  2025cites this paper
• Comparison of Serum USP9x and TGF-β Levels in Children with Autism Spectrum Disorders with Healthy Controls.

  2024cites this paper
• Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities

  2024cites this paper
• Unravelling the critical role of neuroinflammation in epilepsy-associated neuropsychiatric comorbidities: A review.

  2024cites this paper
• UNRAVELING THE COMPLEX GENETIC ARCHITECTURE OF AUTISM SPECTRUM DISORDER: INSIGHTS INTO PATHOPHYSIOLOGY AND THERAPEUTIC IMPLICATIONS

  2024cites this paper
• Autism spectrum disorder and a possible role of anti-inflammatory treatments: experience in the pediatric allergy/immunology clinic

  2024cites this paper
• Emerging drugs for the treatment of irritability associated with autism spectrum disorder

  2024influential citation
• Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).

  2023cites this paper
• Role of oxidative stress in the pathogenesis of autism spectrum disorders

  2023cites this paper
• Microglial contribution to the pathology of neurodevelopmental disorders in humans

  2023cites this paper
• Peripheral Inflammatory Markers in Autism Spectrum Disorder and Attention Deficit/Hyperactivity Disorder at Adolescent Age

  2023cites this paper
• Anti-Inflammatory Therapy as a Promising Target in Neuropsychiatric Disorders.

  2023cites this paper
• Neuroinflammation and Oxidative Stress in the Pathogenesis of Autism Spectrum Disorder

  2023cites this paper
• Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials

  2023cites this paper
• Differences of gut microbiota and behavioral symptoms between two subgroups of autistic children based on γδT cells-derived IFN-γ Levels: A preliminary study

  2023cites this paper
• Repetitive Restricted Behaviors in Autism Spectrum Disorder: From Mechanism to Development of Therapeutics

  2022cites this paper
• Modelling the Interplay Between Neuron-Glia Cell Dysfunction and Glial Therapy in Autism Spectrum Disorder

  2022cites this paper
• The Role of Oxytocin in Abnormal Brain Development: Effect on Glial Cells and Neuroinflammation

  2022cites this paper
• Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive–compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study

  2022cites this paper
• IL-6 and IL-8: An Overview of Their Roles in Healthy and Pathological Pregnancies

  2022cites this paper
• Variation in Response to Pharmacological Intervention with Risperidone and the Role of Adjuvant Medications in the Treatment of Autism Spectrum Disorders: A Systematic Review and Meta-analysis

  2022cites this paper
• Chemical Modulators for Targeting Autism Spectrum Disorders: From Bench to Clinic

  2022influential citation
• Systematic Review and Meta-analysis: Pharmacological and Non-Pharmacological Interventions for Persistent Non-episodic Irritability.

  2022cites this paper
• In vivo imaging translocator protein (TSPO) in autism spectrum disorder

  2022cites this paper
• Autism Spectrum Disorder

  2021cites this paper
• Effects of Celecoxib Adjunct to Selective Serotonin Reuptake Inhibitors on Obsessive-Compulsive Disorder

  2021cites this paper
• Autoimmune Encephalitis and Autism Spectrum Disorder

  2021cites this paper
• Neuropsychiatric disorders: An immunological perspective.

  2021cites this paper
• The Role of Maternal Immune Activation in the Pathogenesis of Autism: A Review of the Evidence, Proposed Mechanisms and Implications for Treatment

  2021cites this paper
• The immune system and autism spectrum disorder: association and therapeutic challenges.

  2021cites this paper
• Multifaceted interconnections between macrophage migration inhibitory factor and psychiatric disorders.

  2021cites this paper
• Étude transversale de prescription hors-AMM des psychotropes chez l’enfant et l’adolescent

  2021cites this paper
• Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis

  2021cites this paper
• [11C]PBR28 MR–PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder

  2020cites this paper
• The interplay between gut microbiota and autism spectrum disorders: A focus on immunological pathways.

  2020cites this paper
• Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders

  2020cites this paper
• Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double‐blind, placebo‐controlled clinical trial

  2020cites this paper
• Prednisolone as Adjunctive Treatment to Risperidone in Children With Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial

  2020cites this paper
• Title: Efficacy of the Addition of Celecoxib to Selective Serotonin Reuptake Inhibitors in Treating Obsessive–Compulsive Disorder: A Double-Blind Clinical Trial Study

  2020cites this paper
• Immune Modulatory Treatments for Autism Spectrum Disorder.

  2020cites this paper
• Neuroinflammation and neuroprotection in schizophrenia and autism spectrum disorder

  2020cites this paper
• Pharmacotherapy of challenging behaviours in children and adolescents with autism spectrum disorder

  2019cites this paper
• Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double‐blind and placebo‐controlled randomized trial

  2019cites this paper
• Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

  2019cites this paper
• Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review

  2019cites this paper
• Characterizing the Interplay Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative Review

  2019cites this paper
• Is psychosis, at least in part, an immune-related dysmyelination disease?

  2019cites this paper
• Targeted biomedical treatment for Autism Spectrum Disorder.

  2019cites this paper
• Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism

  2019cites this paper
• The Contribution of Inflammation to Autism Spectrum Disorders: Recent Clinical Evidence.

  2019cites this paper
• Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder

  2019cites this paper
• A meta-analysis of pro-inflammatory cytokines in autism spectrum disorders: Effects of age, gender, and latitude.

  2019cites this paper
• Microglia as possible therapeutic targets for autism spectrum disorders.

  2019cites this paper
• Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder—An Exploratory Pilot Study †

  2019cites this paper
• Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders

  2019cites this paper
• Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy

  2018cites this paper
• Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial.

  2018cites this paper
• Citicoline (CDP‐choline) add‐on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double‐blind, randomized placebo‐controlled trial

  2018cites this paper
• Systematic review and guide to management of core and psychiatric symptoms in youth with autism

  2018cites this paper
• Monoclonal Antibody for Reducing Memory and Learning Problems in Schizophrenia

  2018cites this paper
• Immune Dysfunction and Autoimmunity as Pathological Mechanisms in Autism Spectrum Disorders

  2018cites this paper
• Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial

  2018cites this paper
• Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive–compulsive disorder: A double‐blind randomized trial with placebo control

  2018cites this paper
• Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial

  2018cites this paper
• Pathogenicity of Endocrine Dysregulation in Autism

  2018cites this paper
• 2Al-Farabi KazNU, Almaty, Kazakhstan ASSOCIATION OF COX-2 GENE POLYMORPHISM WITH AUTISM SPECTRUM DISORDER Autism spectrum disorders (ASD) are heterogeneous diseases that results from the interaction between genetic and environmental factors. There is evidence for inflammation playing a significant r

  2018cites this paper
• Risperidone in Combination With Other Drugs: Experimental Research in Individuals With Autism Spectrum Disorder

  2017cites this paper
• Modulating Neuroinflammation to Treat Neuropsychiatric Disorders

  2017cites this paper
• Immune Endophenotypes in Children With Autism Spectrum Disorder.

  2017cites this paper
• The Immune System, Cytokines, and Biomarkers in Autism Spectrum Disorder

  2017cites this paper
• Long-term altered immune responses following fetal priming in a non-human primate model of maternal immune activation.

  2017cites this paper
• l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

  2017cites this paper
• Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial.

  2017cites this paper
• Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2017cites this paper
• Effects of Celecoxib or Omega-3 Fatty Acids Alone and in Combination with Risperidone on the Behavior and Brain Biochemistry Using Amphetamine-Induced Model of Schizophrenia in Rats

  2016cites this paper
• Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial

  2016cites this paper
• Immune Dysfunction in Autism Spectrum Disorder

  2016cites this paper
• Effects of celecoxib or omega-3 fatty acids alone and in combination with risperidone on the behavior and brain biochemistry in amphetamine-induced model of schizophrenia

  2016cites this paper
• Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis.

  2016cites this paper
• Involvement of Neuroinflammation during Brain Development in Social Cognitive Deficits in Autism Spectrum Disorder and Schizophrenia

  2016cites this paper
• Treatment of Autism Spectrum Disorder in Children and Adolescents.

  2016cites this paper
• Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes

  2016cites this paper
• Redox biology and autism

  2016cites this paper
• Update on psychopharmacology for autism spectrum disorders

  2016cites this paper
• Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.

  2016cites this paper
• A fully automated Drosophila olfactory classical conditioning and testing system for behavioral learning and memory assessment.

  2016cites this paper
• Evidence supporting an altered immune response in ASD.

  2015cites this paper
• Cognitive Enhancement

  2015cites this paper
• Increased Vulnerability to Oxidative Stress and Mitochondrial Dysfunction in Autism

  2015cites this paper
• Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients

  2015cites this paper
• Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases

  2015cites this paper
• Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein

  2015cites this paper
• Exploring the Potential Role of Inflammation as an Etiological Process in ASD

  2015cites this paper
• Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis

  2015influential citation